A phase II trial of MGL-3196 in patients with homozygous familial hypercholesterolemia
Phase of Trial: Phase II
Latest Information Update: 11 May 2017
Price : $35 *
At a glance
- Drugs Resmetirom (Primary)
- Indications Hyperlipoproteinaemia type IIa
- Focus Therapeutic Use
- Sponsors Madrigal Pharmaceuticals
- 11 May 2017 According to a Madrigal Pharmaceuticals media release, the protocol of this trial is in development.
- 10 Apr 2017 New trial record
- 03 Apr 2017 According to a Madrigal Pharmaceuticals media release, this trial is expected to begin enrolling patients by the end of 2017.